Cargando…

Gynecologic large cell neuroendocrine carcinoma: A review

Large cell neuroendocrine carcinomas (LCNEC) are rare, aggressive high-grade neuroendocrine neoplasms within the neuroendocrine cell lineage spectrum. This manuscript provides a detailed review of published literature on LCNEC of gynecological origin. We performed a PubMed search for material availa...

Descripción completa

Detalles Bibliográficos
Autores principales: Burkeen, Grant, Chauhan, Aman, Agrawal, Rohitashva, Raiker, Riva, Kolesar, Jill, Anthony, Lowell, Evers, B. Mark, Arnold, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605029/
https://www.ncbi.nlm.nih.gov/pubmed/33194158
http://dx.doi.org/10.1177/2036361320968401
_version_ 1783604240109797376
author Burkeen, Grant
Chauhan, Aman
Agrawal, Rohitashva
Raiker, Riva
Kolesar, Jill
Anthony, Lowell
Evers, B. Mark
Arnold, Susanne
author_facet Burkeen, Grant
Chauhan, Aman
Agrawal, Rohitashva
Raiker, Riva
Kolesar, Jill
Anthony, Lowell
Evers, B. Mark
Arnold, Susanne
author_sort Burkeen, Grant
collection PubMed
description Large cell neuroendocrine carcinomas (LCNEC) are rare, aggressive high-grade neuroendocrine neoplasms within the neuroendocrine cell lineage spectrum. This manuscript provides a detailed review of published literature on LCNEC of gynecological origin. We performed a PubMed search for material available on gynecologic LCNEC. We analyzed 104 unique cases of gynecologic LCNECs, of which 45 were cervical primary, 45 were ovarian, 13 were uterine, and 1 was vaginal. A total of 45 cases of cervical LCNEC were identified with a median age of 36 years. Median overall survival was 16 months. We identified 45 ovarian LCNEC cases in the published literature with a median age of 54 years. Median overall survival was 8 months. 13 LCNEC cases of uterine origin were identified; 12 out of 13 were of endometrial origin and the median age was 71 years. The majority of patients presented with Stage III/IV disease (stages I–IV were 31%, 8%, 38%, and 23%, respectively). Gynecologic LCNEC is an aggressive malignancy. Our current understanding of the disease biology is very limited. Efforts are required to better understand the genomic and molecular characterizations of gynecological LCNEC. These efforts will elucidate the underlying oncogenic pathways and driver mutations as potential targets.
format Online
Article
Text
id pubmed-7605029
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-76050292020-11-12 Gynecologic large cell neuroendocrine carcinoma: A review Burkeen, Grant Chauhan, Aman Agrawal, Rohitashva Raiker, Riva Kolesar, Jill Anthony, Lowell Evers, B. Mark Arnold, Susanne Rare Tumors Review Large cell neuroendocrine carcinomas (LCNEC) are rare, aggressive high-grade neuroendocrine neoplasms within the neuroendocrine cell lineage spectrum. This manuscript provides a detailed review of published literature on LCNEC of gynecological origin. We performed a PubMed search for material available on gynecologic LCNEC. We analyzed 104 unique cases of gynecologic LCNECs, of which 45 were cervical primary, 45 were ovarian, 13 were uterine, and 1 was vaginal. A total of 45 cases of cervical LCNEC were identified with a median age of 36 years. Median overall survival was 16 months. We identified 45 ovarian LCNEC cases in the published literature with a median age of 54 years. Median overall survival was 8 months. 13 LCNEC cases of uterine origin were identified; 12 out of 13 were of endometrial origin and the median age was 71 years. The majority of patients presented with Stage III/IV disease (stages I–IV were 31%, 8%, 38%, and 23%, respectively). Gynecologic LCNEC is an aggressive malignancy. Our current understanding of the disease biology is very limited. Efforts are required to better understand the genomic and molecular characterizations of gynecological LCNEC. These efforts will elucidate the underlying oncogenic pathways and driver mutations as potential targets. SAGE Publications 2020-10-29 /pmc/articles/PMC7605029/ /pubmed/33194158 http://dx.doi.org/10.1177/2036361320968401 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Burkeen, Grant
Chauhan, Aman
Agrawal, Rohitashva
Raiker, Riva
Kolesar, Jill
Anthony, Lowell
Evers, B. Mark
Arnold, Susanne
Gynecologic large cell neuroendocrine carcinoma: A review
title Gynecologic large cell neuroendocrine carcinoma: A review
title_full Gynecologic large cell neuroendocrine carcinoma: A review
title_fullStr Gynecologic large cell neuroendocrine carcinoma: A review
title_full_unstemmed Gynecologic large cell neuroendocrine carcinoma: A review
title_short Gynecologic large cell neuroendocrine carcinoma: A review
title_sort gynecologic large cell neuroendocrine carcinoma: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605029/
https://www.ncbi.nlm.nih.gov/pubmed/33194158
http://dx.doi.org/10.1177/2036361320968401
work_keys_str_mv AT burkeengrant gynecologiclargecellneuroendocrinecarcinomaareview
AT chauhanaman gynecologiclargecellneuroendocrinecarcinomaareview
AT agrawalrohitashva gynecologiclargecellneuroendocrinecarcinomaareview
AT raikerriva gynecologiclargecellneuroendocrinecarcinomaareview
AT kolesarjill gynecologiclargecellneuroendocrinecarcinomaareview
AT anthonylowell gynecologiclargecellneuroendocrinecarcinomaareview
AT eversbmark gynecologiclargecellneuroendocrinecarcinomaareview
AT arnoldsusanne gynecologiclargecellneuroendocrinecarcinomaareview